<?xml version='1.0' encoding='utf-8'?>
<document id="29468841"><sentence text="Development, Verification, and Prediction of Osimertinib Drug-Drug Interactions Using PBPK Modeling Approach to Inform Drug Label."><entity charOffset="45-56" id="DDI-PubMed.29468841.s1.e0" text="Osimertinib" /></sentence><sentence text="Osimertinib is a potent, highly selective, irreversible inhibitor of epidermal growth factor receptor (EGFR) and T790M resistance mutation"><entity charOffset="0-11" id="DDI-PubMed.29468841.s2.e0" text="Osimertinib" /></sentence><sentence text=" In vitro metabolism data suggested osimertinib is a substrate of cytochrome P450 (CYP)3A4/5, a weak inducer of CYP3A, and an inhibitor of breast cancer resistance protein (BCRP)"><entity charOffset="36-47" id="DDI-PubMed.29468841.s3.e0" text="osimertinib" /></sentence><sentence text=" A combination of in vitro data, clinical pharmacokinetic data, and drug-drug interaction (DDI) data of osimertinib in oncology patients were used to develop the physiologically based pharmacokinetic (PBPK) model and verify the DDI data of osimertinib"><entity charOffset="104-115" id="DDI-PubMed.29468841.s4.e0" text="osimertinib" /><entity charOffset="240-251" id="DDI-PubMed.29468841.s4.e1" text="osimertinib" /><pair ddi="false" e1="DDI-PubMed.29468841.s4.e0" e2="DDI-PubMed.29468841.s4.e0" /><pair ddi="false" e1="DDI-PubMed.29468841.s4.e0" e2="DDI-PubMed.29468841.s4.e1" /></sentence><sentence text=" The model predicted the observed monotherapy concentration profile of osimertinib within 1"><entity charOffset="71-82" id="DDI-PubMed.29468841.s5.e0" text="osimertinib" /></sentence><sentence text="1-fold, and showed good predictability (within 1" /><sentence text="7-fold) to the observed peak plasma concentration (Cmax ) and area under the curve (AUC) DDI ratio changes, when co-administered with rifampicin, itraconazole, and simvastatin, but not with rosuvastatin"><entity charOffset="134-144" id="DDI-PubMed.29468841.s7.e0" text="rifampicin" /><entity charOffset="146-158" id="DDI-PubMed.29468841.s7.e1" text="itraconazole" /><entity charOffset="164-175" id="DDI-PubMed.29468841.s7.e2" text="simvastatin" /><entity charOffset="190-202" id="DDI-PubMed.29468841.s7.e3" text="rosuvastatin" /><pair ddi="false" e1="DDI-PubMed.29468841.s7.e0" e2="DDI-PubMed.29468841.s7.e0" /><pair ddi="false" e1="DDI-PubMed.29468841.s7.e0" e2="DDI-PubMed.29468841.s7.e1" /><pair ddi="false" e1="DDI-PubMed.29468841.s7.e0" e2="DDI-PubMed.29468841.s7.e2" /><pair ddi="false" e1="DDI-PubMed.29468841.s7.e0" e2="DDI-PubMed.29468841.s7.e3" /><pair ddi="false" e1="DDI-PubMed.29468841.s7.e1" e2="DDI-PubMed.29468841.s7.e1" /><pair ddi="false" e1="DDI-PubMed.29468841.s7.e1" e2="DDI-PubMed.29468841.s7.e2" /><pair ddi="false" e1="DDI-PubMed.29468841.s7.e1" e2="DDI-PubMed.29468841.s7.e3" /><pair ddi="false" e1="DDI-PubMed.29468841.s7.e2" e2="DDI-PubMed.29468841.s7.e2" /><pair ddi="false" e1="DDI-PubMed.29468841.s7.e2" e2="DDI-PubMed.29468841.s7.e3" /></sentence><sentence text=" Based on observed clinical data and PBPK simulations, the recommended dose of osimertinib when dosed with strong CYP3A inducers is 160 mg once daily"><entity charOffset="79-90" id="DDI-PubMed.29468841.s8.e0" text="osimertinib" /></sentence><sentence text=" PBPK modeling suggested no dose adjustment with moderate and weak CYP3A inducers" /><sentence text="" /></document>